Soligenix, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:SNGX) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 7.75 M5.76 M11.29 M9.24 M6.92 M Total liabilities 4.13 M3.93 M3.7 M3.94 M3.83 M Total equity 3.61 M1.83 M7.6 M5.29 M3.09 M Total liabilities & shareholders' equities 7.75 M5.76 M11.29 M9.24 M6.92 M Total debt ————— Net debt —————

News

Soligenix (SNGX) Stock Soars 72% On ThermoVax Platform Promise Amid Ebola Outbreak Caused By Bundibugyo V

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.06%

Soligenix receives UK regulatory designation for Behçet’s drug

Soligenix receives positive EMA opinion for orphan drug status

Soligenix stock rises after positive Behçet’s Disease treatment data

Soligenix reports positive results from SGX945 trial for Behçet’s disease

Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel - Soligenix (NASDAQ:SNGX)

Soligenix reports positive results from psoriasis gel treatment trial

First patient dosed in Synairgen’s global phase 2 INVENT study

Soligenix hits enrollment target for CTCL treatment interim analysis

Soligenix updates medical advisory board for lymphoma treatment

Soligenix stock soars after DMC confirms safety in Phase 3 CTCL study